|
|
Vaccine Detail
|
Pandemrix |
| Vaccine Information |
- Vaccine Name: Pandemrix
- Target Pathogen: Influenza virus
- Target Disease: Influenza (flu)
- Tradename: Pandemrix
- Manufacturer: GlaxoSmithKline
- Vaccine Ontology ID: VO_0000410
- Type: Inactivated or "killed" vaccine
- Status: Licensed
- Location Licensed: European Union
- Host Species for Licensed Use: Human
- Antigen: After mixing, 1 dose (0.5 ml) contains: Split influenza virus, inactivated, containing antigen equivalent to: - A/California/07/2009 (H1N1) derived strain used NYMC X-179A 3.75 micrograms.
The virus is propagated in eggs. It contains haemagglutinin (EMA Pandemrix Suppl, 2013).
- Adjuvant:
- Adjuvant name:
- VO adjuvant ID: VO_0001320
- Description: AS03 adjuvant composed of squalene (10.69 milligrams), DL-α-tocopherol (11.86 milligrams) and polysorbate 80 (4.86 milligrams) (EMA Pandemrix Suppl, 2013)
- Preservative: thiomersal
- Immunization Route: Intramuscular injection (i.m.)
- Description: Pandemrix is a vaccine to protect against flu caused by the A (H1N1)v 2009 virus. In people under 20 years of age, Pandemrix should only be used if the recommended annual seasonal trivalent influenza vaccine is not available and if immunisation against (H1N1)v is considered necessary (EMA Pandemrix, 2013).
|
| Host Response |
|
|
| References |
EMA Pandemrix Suppl, 2013: EMA Pandemrix Summary of Product Characteristics [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000832/WC500038121.pdf]
EMA Pandemrix, 2013: European Medicines Agency (EMA) Pandemrix [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000832/human_med_000965.jsp&mid=WC0b01ac058001d124]
|
|
